Valuation: Mabion S.A.

Market Cap 127M 33.51M 29.28M 27.02M 24.91M 46.95M 3.23B 47.99M 323M 1.58B 126M 123M 5.44B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 133M 35.17M 30.74M 28.37M 26.15M 49.28M 3.39B 50.37M 339M 1.66B 132M 129M 5.71B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
67.18%
Yield 2024 *
-
Yield 2025 -
1 day+3.15%
1 week+6.50%
Current month+5.36%
1 month+0.38%
3 months-7.09%
6 months-4.15%
Current year+12.61%
1 week 7.23
Extreme 7.23
7.96
1 month 7.16
Extreme 7.16
7.96
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
110
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 2021-02-22
Chairman 60 2021-05-12
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.15%+6.50%-17.26%-56.21% 33.51M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.18%-1.71%+34.76%+160.02% 23.36B
Weighted average by Cap. -2.80%-2.35%+39.54%+143.10%

Financials

2024 2025
Net sales 69.02 18.21 15.91 14.68 13.53 25.51 1.75K 26.07 175.48 858.66 68.37 66.87 2.96K 15.76 4.16 3.63 3.35 3.09 5.82 400.26 5.95 40.06 196.03 15.61 15.27 674.83
Net income -6.33M -1.67M -1.46M -1.35M -1.24M -2.34M -161M -2.39M -16.1M -78.8M -6.27M -6.14M -271M -62.61M -16.52M -14.43M -13.32M -12.28M -23.14M -1.59B -23.65M -159M -779M -62.03M -60.67M -2.68B
Net Debt -35.18M -9.28M -8.11M -7.48M -6.9M -13M -894M -13.29M -89.46M -438M -34.85M -34.09M -1.51B 6.32M 1.67M 1.46M 1.34M 1.24M 2.33M 160M 2.39M 16.06M 78.58M 6.26M 6.12M 270M
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
26-07-17 PLN 7.860 +3.15% 53,253
26-07-16 PLN 7.620 +2.14% 15,731
26-07-15 PLN 7.460 +0.54% 8,101
26-07-14 PLN 7.420 +1.64% 4,763
26-07-13 PLN 7.300 -1.08% 5,282

Quarterly revenue - Rate of surprise